Idylla assay on extracted DNA: advantages, limits and place in molecular screening according to the latest guidelines for non-small-cell lung cancer (NSCLC) patients.

Fiche publication

Date publication

juillet 2022

Journal

Journal of clinical pathology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CHAPUSOT Caroline , Pr MARTIN Laurent

Tous les auteurs :
Khalifa E, Chapusot C, Tournier B, Sentis J, Marion E, Remond A, Aubry M, Pioche C, Bergeron A, Primois C, Blanchard L, Millière A, Boucheix M, Léger Y, Bairrao M, Brouste V, Martin L, Soubeyran I

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35820776

Résumé

Idylla epidermal growth factor receptor () is a fast and fully automated mutation assay that is easy to implement. However, under the Biocartis-recommended technical conditions, tissue sections are directly introduced into the cartridge, at the risk of exhausting the tumour sample. In this study, we evaluate the performance of Idylla on extracted DNA and discuss its place within the global non-small-cell lung cancer (NSCLC) screening strategy.